Multiple myeloma is a cancer that develops in the bone marrow, the spongy tissue found in the center of most bones. Multiple myeloma is characterized by abnormalities in plasma cells, a type of white blood cell. These abnormal cells multiply out of control, increasing from about one percent of cells in the bone marrow to the majority of bone marrow cells. The abnormal cells form tumors within the bone, causing bone pain and an increased risk of fractures.
Disease: Multiple Myeloma, MM, (NCT04244656)
Study Director:Ewelina Morawa, MDCRISPR Therapeutics
Portland, Oregon, United States
Nashville, Tennessee, United States
Melbourne, Victoria, Australia
Illinois, United States
Sydney, New South Wales, Australia
Pamplona, Navarra, Spain
Status: Active recruiting
This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple myeloma.
CTX120 B-cell maturation antigen (BCMA)-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
CTX120 is an allogeneic CRISPR-Cas9 gene-edited CAR-T cell therapy targeting BCMA for the treatment of multiple myelomaLast updated: Aug. 1, 2020